Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cevimeline - Daiichi Sankyo

Drug Profile

Cevimeline - Daiichi Sankyo

Alternative Names: AF 102B; Cevimeline hydrochloride; Evoxac; FKS 508; Saligren; SND 5088; SNI 2011; SNK 508

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Israel Institute for Biological Research
  • Developer Daiichi Sankyo Company; Nippon Kayaku; SnowBrand Pharmaceuticals
  • Class Quinuclidines; Small molecules; Thiophenes
  • Mechanism of Action Muscarinic M1 receptor agonists; Muscarinic M3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Xerostomia
  • Discontinued Alzheimer's disease

Most Recent Events

  • 18 Jan 2022 Cevimeline licensed to Cosette Pharmaceuticals in USA
  • 26 Feb 2021 Daiichi Sankyo Company plans to transfer rights of Evoxac to Alfresa Pharma by December 2021
  • 09 Oct 2012 Authorised generic equivalent available in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top